Enfortumab vedotin, an ADC consisting of a fully human monoclonal antibody specific for nectin-4 and monomethyl auristatin E (MMAE), was approved in 2019 for advanced BC patients who progressed on a regimen of platinum-based chemotherapy and PD1/PD-L1 inhibitors [33]. Here, CD274 is linked to breast cancer.